Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M116,373Revenue $M50,196Net Margin (%)8.9Z-Score2.6
Enterprise Value $M123,214EPS $4.8Operating Margin %12.3F-Score7
P/E(ttm))26.1Cash Flow Per Share $0Pre-tax Margin (%)11.9Higher ROA y-yY
Price/Book4.710-y EBITDA Growth Rate %6.0Quick Ratio1.2Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %2.7Current Ratio1.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %9.3ROA % (ttm)6.6Higher Current Ratio y-yY
Dividend Yield %1.5Insider Buy (3m)0ROE % (ttm)18.0Less Shares Outstanding y-yY
Payout Ratio %34.0Shares Outstanding M827ROI % (ttm)11.0Gross Margin Increase y-yN

Gurus Latest Trades with BAYRY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAYRYKen Fisher 2014-06-30 Add0.6%$126.84 - $144.81
($138.38)
$ 140.732%Add 750.48%2,302,369
BAYRYKen Fisher 2014-03-31 Add0.06%$128.3 - $142.7
($135.49)
$ 140.734%Add 217.05%270,713
BAYRYKen Fisher 2013-06-30 Add0.01%$101 - $112.75
($106.88)
$ 140.7332%Add 34.62%84,456
BAYRYVanguard Health Care Fund 2012-12-31 Reduce-0.21%$83.28 - $96.38
($89.59)
$ 140.7357%Reduce -21.2%2,044,656
BAYRYKen Fisher 2012-09-30 Buy 0.02%$68.01 - $88.62
($77.14)
$ 140.7382%New holding, 72838 sh.72,838
BAYRYKen Fisher 2012-03-31 Sold Out -0.01%$0.04 - $75.15
($59.98)
$ 140.73135%Sold Out0
BAYRYKen Fisher 2009-06-30 Sold Out $47.66 - $59.35
($52.77)
$ 140.73167%Sold Out0
BAYRYJohn Keeley 2009-06-30 Sold Out -0.01%$47.66 - $59.35
($52.77)
$ 140.73167%Sold Out0
BAYRYJohn Keeley 2009-03-31 Buy 0.01%$43.75 - $59.4
($52.7)
$ 140.73167%New holding, 6500 sh.6,500
BAYRYJohn Keeley 2008-03-31 Sold Out -0.01%$69.76 - $92.41
($78.8)
$ 140.7379%Sold Out0
BAYRYJohn Keeley 2007-09-30 Buy $68.04 - $79.44
($75.7)
$ 140.7386%New holding, 11000 sh.11,000
BAYRYVanguard Health Care Fund 2007-03-31 Reduce-1.27%$52.14 - $61.01
($56.7)
$ 140.73148%Reduce -22.24%5,944,656
BAYRYVanguard Health Care Fund 2006-09-30 Add1.48%$45.67 - $50.95
($48.9)
$ 140.73188%Add 1811.16%7,644,656
BAYRYKen Fisher 2006-04-27 Buy Premium Member Access $40 $ 140.73252%P/E=12
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAYRY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BAYRY Ken Fisher 2014-09-302,511,3640.30.75+9.08%
Premium Most recent portfolio changes are included for Premium Members only!


BAYRY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about BAYRY :

    Quarterly/Annual Reports about BAYRY:

      News about BAYRY:

      Articles On GuruFocus.com
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
      Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
      We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
      Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
      Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
      Pfizer: A Strong Stock for 2013 Apr 20 2012 
      Maxygen Inc. (MAXY): A Magic Formula Stock to Avoid Feb 05 2009 


      More From Other Websites
      Bayer to divest equine assets to Merial -- Divestiture includes Legend® /Hyonate® (hyaluronate... Dec 17 2014
      ISIS Jumps on Positive Results for Venous Thrombosis Drug Dec 09 2014
      Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River... Dec 09 2014
      Inauguration of the TDI-plant Dormagen -- Address by André van Broich -- Chairman of the Works... Dec 09 2014
      Inauguration of the TDI-plant Dormagen -- Adress by Dr. Marijn Dekkers -- Chairman of the Board of... Dec 09 2014
      Inauguration of the TDI-plant Dormagen -- Adress by Patrick Thomas -- Chairman of the Board of... Dec 09 2014
      Bayer Files Hemophilia A Drug Marketing Application in EU Dec 05 2014
      Regeneron at 52-Week High on Eylea Priority Review Status Dec 04 2014
      Moody's: Deutsche Anleihe-Emissionen dürften langsamen Wachstumstrend 2015 fortsetzen Dec 03 2014
      Actelion Submits Marketing Application for Uptravi in EU Dec 03 2014
      Bee health magazine “BEENOW” launched at Bayer’s Perspective on Innovation 2014: -- Partnering... Dec 03 2014
      Regeneron/Bayer's Eylea to be Reviewed on a Priority Basis Dec 02 2014
      Press Forum: “Bayer’s Perspective on Innovation 2014” -- Address by Kemal Malik -- Member of... Dec 02 2014
      Press Forum: “Bayer’s Perspective on Innovation 2014” -- Address by Dr. Marijn Dekkers --... Dec 02 2014
      Life science company Bayer steps up focus on research and development Dec 02 2014
      An Eye on the Heavens Nov 29 2014
      Bayer CropScience opens Weed Resistance Competence Center in Frankfurt, Germany -- Major step... Nov 20 2014
      Regeneron/Bayer's Eylea Gets Japanese Approval for DME Nov 19 2014
      Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning Nov 17 2014
      Dr. Klaus Schäfer to assume new position January 1, 2015 -- New head of Industrial Operations at... Nov 12 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK